Related Experiment Video
Updated: Dec 14, 2025
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
Increased levels of platelet-derived microparticles in pulmonary hypertension
Aiko Ogawa1, Hiromi Matsubara2
1Division of Molecular and Cellular Medicine, Department of Clinical Science, National Hospital Organization Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama 701-1192, Japan.
Introduction:
Thrombosis and coagulation abnormalities are thought to be involved in disease progression of pulmonary hypertension. Platelet-derived microparticles (PDMP) are released from platelets following stimulation and have recently been demonstrated to play an important role in pathogenesis of various diseases. This study aimed to evaluate PDMP levels in patients with pulmonary hypertension.
Materials And Methods:
Our cross-sectional study enrolled a total of 113 participants including 73 patients with pulmonary hypertension and 40 participants to serve as a control group. PDMP levels were measured using a PDMP ELISA kit, which detects glycoproteins CD42a and CD42b. Clinical parameters, including exercise capacity and hemodynamic parameters, were collected, and the relationship to PDMP levels were evaluated.
Results:
PDMP levels were significantly higher in patients than in participants in the control group (23.2 ± 39.4 U/mL and 7.8 ± 3.6 U/mL, respectively, P < 0.05). PDMP levels in patients with chronic thromboembolic pulmonary hypertension were correlated with right atrial pressure and cardiac index. PDMP levels were higher in male patients with idiopathic pulmonary arterial hypertension. Furthermore, patients administered a higher dose of epoprostenol had a tendency for lower PDMP levels.
Conclusions:
The data suggest that PDMP levels are increased in patients with pulmonary hypertension. Further study is needed to understand the mechanism and impact of PDMP on disease progression.
Insights
Platelet-derived microparticles (PDMP) are elevated in pulmonary hypertension patients, correlating with disease severity and potentially offering therapeutic insights. Further research is needed to explore their role in disease progression.
Area of Science:
- Cardiovascular Research
- Hematology
- Pulmonary Medicine
Background:
- Thrombosis and coagulation disorders are implicated in pulmonary hypertension (PH) progression.
- Platelet-derived microparticles (PDMP) are key mediators in various disease pathologies.
- The role of PDMP in PH pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate and quantify Platelet-derived microparticles (PDMP) levels in patients diagnosed with pulmonary hypertension.
- To explore the correlation between PDMP levels and clinical/hemodynamic parameters in PH patients.
Main Methods:
- A cross-sectional study involving 73 PH patients and 40 controls.
- Measurement of PDMP levels using a specific ELISA kit (detecting CD42a and CD42b glycoproteins).
- Analysis of clinical and hemodynamic data, including exercise capacity and right atrial pressure.
Main Results:
- Significantly higher PDMP levels were observed in PH patients compared to controls (23.2 ± 39.4 U/mL vs. 7.8 ± 3.6 U/mL, P < 0.05).
- In chronic thromboembolic PH, PDMP levels correlated with right atrial pressure and cardiac index.
- Elevated PDMP levels were noted in male idiopathic pulmonary arterial hypertension patients; higher epoprostenol doses showed a trend towards lower PDMP.
Conclusions:
- PDMP levels are demonstrably increased in individuals with pulmonary hypertension.
- Further investigation is warranted to understand the precise mechanisms and clinical impact of PDMP in PH progression.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...